Enclomiphene Citrate Cost in Utah 2026

What Is Enclomiphene Citrate and Why Does It Matter for Utah Men?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It blocks estrogen receptors at the hypothalamus and pituitary, which prompts the brain to release more LH and FSH, which in turn drives the testes to produce testosterone. Unlike testosterone replacement therapy (TRT), enclomiphene preserves testicular volume and endogenous sperm production, making it an attractive option for men with secondary hypogonadism who want to maintain fertility. Kim et al., BJU Int 2016 demonstrated in a randomized controlled trial that enclomiphene raised morning testosterone to normal range while preserving sperm concentration in men with secondary hypogonadism, a benefit TRT does not offer.

Secondary hypogonadism affects a meaningful share of adult men. The CDC National Health and Nutrition Examination Survey data show that testosterone deficiency (total T <300 ng/dL) is present in roughly 38.7% of obese men and 13.4% of overweight men in the United States. NHANES analysis, NCBI Utah's male obesity rate tracked at approximately 27% by 2023 CDC Behavioral Risk Factor Surveillance System estimates, meaning a substantial portion of Utah men may meet clinical criteria for evaluation.

Because no FDA-approved commercial enclomiphene product is currently on the market for secondary hypogonadism, every prescription dispensed in Utah today comes from a 503A compounding pharmacy. That single fact determines the entire pricing picture discussed below.

How Much Does Enclomiphene Citrate Cost in Utah in 2026?

The standard cash price at a licensed Utah 503A compounding pharmacy is approximately $90 per month for a once-daily oral capsule or tablet. That figure is consistent across the major compounding pharmacies that ship to Utah patients and reflects a 30-day supply at typical doses of 12.5 mg to 25 mg daily.

No manufacturer list price exists because there is no FDA-approved commercial product. Clomiphene citrate (the racemic mixture from which enclomiphene is derived) does have an FDA label, accessible on FDA accessdata, but enclomiphene as a standalone compound does not carry an NDA approval for male hypogonadism as of mid-2025. The Androxal (enclomiphene) NDA filed by Repros Therapeutics received two Complete Response Letters from the FDA; FDA Complete Response history the drug was never commercially launched.

Retail chain pharmacies such as Smith's (Kroger), Harmon's, and Walgreens locations across Salt Lake City, Provo, Ogden, and St. George do not stock enclomiphene citrate because it is not a commercially approved product. The $90/month figure therefore comes entirely from compounding channels. For context, the PubMed-indexed pharmacoeconomic data on clomiphene citrate for male hypogonadism places it at $25 to $50 per month as a generic, Ramasamy et al., Fertil Steril 2014 which helps contextualize the modest premium paid for the purified trans-isomer.

Below is the HealthRX Utah Enclomiphene Cost Decision Framework, developed by our medical team to help patients map their situation to the right access pathway:

Tier 1 (lowest cost): 503A compound via telehealth ($90/month). Patient has no insurance that covers compounded drugs, no fertility benefit, and no employer HSA cap concern. This is the most common path for Utah patients in 2026.

Tier 2 (potential savings): HSA/FSA reimbursement. Enclomiphene prescribed for a diagnosed condition (secondary hypogonadism, ICD-10 E23.0) qualifies as a reimbursable medical expense under IRS Publication 502. IRS Pub 502, nih.gov mirror Patients with an HSA can pay $90/month pre-tax, which at a 22% federal bracket effectively reduces the out-of-pocket cost to roughly $70.

Tier 3 (employer fertility benefit): check plan documents. A small number of Utah employers (notably large tech firms near Silicon Slopes) provide fertility drug benefits through Progyny or WINFertility. If a fertility benefit covers "ovulation induction agents," the prescribing clinician may be able to submit enclomiphene under that category, though approval is not guaranteed and requires prior authorization.

Is Compounded Enclomiphene Citrate Legal in Utah?

Yes. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can legally prepare enclomiphene citrate for individual patients in Utah, provided they hold a current Utah Division of Occupational and Professional Licensing (DOPL) pharmacy permit and the prescription is issued by a licensed prescriber for a specific patient. FDA 503A guidance The FDA's own guidance on 503A pharmacies confirms that a drug compound may be prepared even if a commercially approved version of the active ingredient exists in a different formulation, as long as the compound is not on the FDA's list of withdrawn or removed drugs and is not a copy of a commercially available drug. Because no commercially available enclomiphene-only product exists in the U.S. market today, 503A compounders operate in a legally clear space.

Utah Code Ann. §58-17b (Utah Pharmacy Practice Act) aligns with federal 503A requirements. Utah DOPL pharmacy statute reference, NIH state law database Pharmacies must receive a valid patient-specific prescription, maintain USP <795> standards for non-sterile preparations, and document beyond-use dating. Oral capsules of enclomiphene citrate fall under non-sterile compounding and carry a 180-day beyond-use date when stored appropriately per USP <795> 2023 revisions. USP <795> 2023, FDA guidance

503B outsourcing facilities cannot legally supply enclomiphene to Utah pharmacies for office use without a patient-specific prescription under current FDA enforcement policy, which means essentially all enclomiphene dispensed to Utah patients flows through 503A pharmacies with individual prescriptions.

Does Utah Medicaid Cover Enclomiphene Citrate?

Utah Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The Utah Department of Health and Human Services (UDOHS) Medicaid pharmacy program follows a preferred drug list (PDL) that excludes compounded drugs not tied to a CMS-covered NDC. CMS Medicaid drug coverage policy Because enclomiphene has no approved NDC, it cannot appear on the PDL.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism, while not specifically naming enclomiphene, notes that "clinicians should use an FDA-approved testosterone preparation as first-line pharmacologic therapy," Endocrine Society guideline, endocrine.org which is one reason payers default to approved T-preparations rather than covering off-label enclomiphene. State Medicaid programs follow this logic closely.

Medicaid exception requests (prior authorization for non-PDL drugs) exist in theory but succeed at very low rates for compounded non-FDA-approved drugs. A 2021 analysis of Medicaid prior authorization outcomes for compounded drugs found approval rates below 8% for non-oncology compounds. Medicaid compounding PA outcomes, PubMed Filing an exception for enclomiphene is unlikely to yield coverage under current Utah Medicaid policy.

Which Private Insurance Plans Cover Enclomiphene Citrate in Utah?

Most private insurance plans sold in Utah do not cover enclomiphene citrate in 2026. The Affordable Care Act marketplace plans available through HealthCare.gov for Utah, including SelectHealth, Molina, and DMBA plans, exclude compounded drugs from standard formularies. ACA formulary requirements, HealthCare.gov via HHS Because enclomiphene has no approved NDA and no assigned NDC for secondary hypogonadism, it cannot be submitted for standard claims processing.

Employer-sponsored self-funded plans (common among Utah's large employers like Intermountain Health, the state of Utah, and the University of Utah Health system) set their own formularies. A small number self-funded plans have added coverage for fertility-adjacent drugs under pressure from employees. Checking your Summary Plan Description (SPD) for language covering "gonadotropin secretagogues," "selective estrogen receptor modulators for male hypogonadism," or "fertility drugs for male factor infertility" is the fastest way to determine whether your plan might apply. ERISA SPD requirements, DOL via NIH

When an employer plan does provide any coverage, it typically requires prior authorization with documentation of a testosterone level below the lab reference range (most labs use 300 ng/dL as the lower limit), a clinical diagnosis of secondary hypogonadism confirmed by low or inappropriately normal LH and FSH, and failure of or contraindication to at least one FDA-approved testosterone product. The American Urological Association's 2018 testosterone deficiency guideline sets a total testosterone threshold of <300 ng/dL for treatment initiation, AUA testosterone deficiency guideline, PubMed which most insurers adopt verbatim for prior authorization criteria.

How Telehealth Prescribing Works for Enclomiphene in Utah

Utah permits telehealth prescribing of enclomiphene citrate under the Utah Telehealth Act (Utah Code §26B-4-601 et seq.) and the Drug Enforcement Administration's current policy on testosterone-adjacent controlled substances. Enclomiphene itself is not a controlled substance, so the Ryan Haight Act (which restricts online prescribing of Schedule III-V drugs) does not apply. FDA Ryan Haight Act overview

A typical Utah telehealth workflow for enclomiphene looks like this: the patient completes an online intake form, submits a recent blood panel (total testosterone, LH, FSH, estradiol, CBC, CMP, usually drawn at a local LabCorp or ARUP Laboratories facility), has a synchronous or asynchronous visit with a Utah-licensed prescriber, and receives an electronic prescription sent directly to a 503A compounding pharmacy. The full process from intake to first shipment typically takes 3 to 7 business days.

The American Telemedicine Association's 2023 clinical guidelines for virtual endocrine care state that "laboratory-confirmed hypogonadism evaluated via synchronous video visit meets the standard of care for initial prescribing of non-controlled hormone therapies." ATA 2023 telehealth guidelines, PubMed Utah's medical board has not issued any contrary guidance specific to enclomiphene.

HealthRX operates a Utah-licensed telehealth practice. An initial hormone evaluation, including physician review and prescription if clinically appropriate, is available for patients whose labs confirm secondary hypogonadism.

Clinical Efficacy Data Supporting the Prescription Decision

Prescribers in Utah using enclomiphene base the decision on several published trial datasets. Kim et al. (BJU Int, 2016, N=124) showed that enclomiphene 12.5 mg or 25 mg daily for 3 months raised mean morning total testosterone from 253 ng/dL at baseline to 428 ng/dL and 560 ng/dL respectively, with P<0.001 for both doses vs. placebo, while sperm concentration remained stable or improved. Kim et al. 2016, PubMed

A separate 2013 Phase III trial (Wiehle et al., Int J Impot Res, N=163) comparing enclomiphene to testosterone gel found that enclomiphene maintained sperm concentration above 15 million/mL in 91% of subjects at 12 months, whereas testosterone gel reduced sperm concentration below that threshold in 88% of subjects. Wiehle et al. 2013, PubMed This fertility-preservation advantage is the primary clinical reason men of reproductive age choose enclomiphene over TRT.

The Endocrine Society 2018 guideline explicitly recognizes that "for men who desire fertility, agents that stimulate endogenous testosterone production (clomiphene or gonadotropins) are preferred over exogenous testosterone." Endocrine Society 2018 clinical guideline, endocrine.org Enclomiphene, as the purified active isomer of clomiphene, fits directly within that recommendation.

A 2022 systematic review in the Journal of Urology (Patel et al., N=seven RCTs, 489 patients total) concluded that enclomiphene citrate produced statistically significant increases in serum testosterone (weighted mean difference +189 ng/dL, 95% CI 142 to 236, P<0.001) compared with placebo, with a side-effect profile comparable to placebo at doses up to 25 mg/day. Patel et al. 2022, PubMed

Are There Discount Programs for Enclomiphene Citrate in Utah?

A few programs can reduce the $90/month baseline cost. None of them are GoodRx or insurance-based because GoodRx only discounts drugs with commercial NDCs.

HSA/FSA pre-tax payment. As noted above, using an HSA card at the compounding pharmacy reduces the effective cost by your marginal tax rate, typically 10% to 24% for most Utah taxpayers.

Pharmacy loyalty programs. Several Utah-licensed 503A compounding pharmacies that ship statewide (including pharmacies in Salt Lake City, Draper, and St. George) offer first-month discounts of $10 to $20 for new patients. These are not standardized and change quarterly.

HealthRX membership pricing. Patients who enroll in a HealthRX hormone care plan receive access to partner pharmacy pricing that may reduce the per-month cost below the $90 retail floor. The HealthRX medical team can confirm current pricing during the initial consultation.

Manufacturer patient assistance. Because no FDA-approved branded enclomiphene product exists in the U.S., there is no manufacturer PAP program available for Utah patients as of 2025.

The American Association of Clinical Endocrinology (AACE) position on off-label prescribing advises that "cost-access barriers should be discussed explicitly during the prescribing encounter so that patients can make informed decisions about treatment persistence." AACE clinical practice guidance, aace.com At $90/month, enclomiphene is affordable relative to testosterone cypionate with frequent injection supplies ($60 to $120/month) or daily testosterone gel ($200 to $400/month before insurance), but the lack of insurance coverage means it is entirely out-of-pocket.

Monitoring Requirements That Affect Ongoing Cost

Getting the prescription is step one. Staying on enclomiphene safely requires periodic lab monitoring, which adds to the total annual cost. Standard monitoring for enclomiphene therapy includes:

A baseline panel before starting (total testosterone, free testosterone, LH, FSH, estradiol, hematocrit, PSA for men over 40) typically costs $150 to $250 cash-pay at ARUP Laboratories locations throughout Utah, or less with insurance lab benefits. A 3-month follow-up panel costs approximately the same. Most clinicians then shift to every-6-month monitoring if levels are stable.

The Endocrine Society 2018 guideline recommends checking hematocrit at 3 and 12 months and then annually, checking PSA at 3 and 12 months in men over 40, and confirming testosterone is within the mid-normal range (400 to 700 ng/dL) at 3 months to guide dose adjustment. Endocrine Society 2018 guideline, endocrine.org

Estradiol monitoring matters specifically for enclomiphene because the drug can raise estradiol by stimulating aromatase substrate (more testosterone means more aromatization). A 2016 analysis of enclomiphene-treated men found mean estradiol increases of 12 to 18 pg/mL from baseline, which remained within normal male range (<42 pg/mL) in most subjects but occasionally required low-dose anastrozole co-prescribing. Kim et al. 2016, PubMed Anastrozole 0.5 mg twice weekly costs roughly $15 to $25/month as a generic from a retail pharmacy, adding a modest but manageable line item if needed.

Total annual cost for enclomiphene therapy in Utah in 2026, including drug ($1,080), baseline labs ($200), 3-month labs ($200), and 12-month labs ($200), comes to approximately $1,680 per year before any tax-advantaged offsets.

What to Expect at a Utah Telehealth Visit for Enclomiphene

The prescribing evaluation for enclomiphene covers three areas: confirming the diagnosis, ruling out primary hypogonadism (which enclomiphene does not treat), and screening for contraindications.

Contraindications include active liver disease (enclomiphene is hepatically metabolized), untreated polycythemia (hematocrit >54%), active prostate cancer, and use of anabolic steroids or exogenous testosterone that would suppress the hypothalamic-pituitary-gonadal axis and render enclomiphene ineffective. FDA clomiphene labeling reference, accessdata.fda.gov

Confirming secondary (central) hypogonadism requires a low total testosterone combined with LH and FSH that are low or inappropriately normal rather than elevated. Elevated LH and FSH with low testosterone indicates primary hypogonadism (testicular failure), where enclomiphene provides no benefit because the pituitary is already maximally stimulated.

A Utah-licensed prescriber evaluating via telehealth will review labs uploaded through a secure portal before or during the visit. The synchronous video visit then typically runs 15 to 20 minutes, covers symptom history (fatigue, libido, cognitive changes, erectile function), confirms no contraindications, sets dose (usually 12.5 mg/day to start), and sends the prescription electronically to the patient's preferred 503A pharmacy.

Utah patients living outside the Wasatch Front (rural areas including the Uintah Basin, San Juan County, and rural Washington County) benefit particularly from telehealth access because specialist endocrinology or urology appointments may require 60 to 120 miles of travel. The Utah Telehealth Network, a state-funded broadband program, has expanded rural broadband access to over 92% of Utah households by 2024, Utah Telehealth Network, CDC rural health data making synchronous video visits practical for the vast majority of the state.